Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
Neuropace股價上漲，公司報告Q3財務業績好於預期，並提高了FY24銷售指引。富國銀行對該股維持超配評級。
Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
Neuropace的股票在公司發佈超出預期的第三季度財務結果並上調2024財年銷售指引後交易上漲。富國銀行對該股票維持超配評級。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間